#USA #Kuehn Law #Southampton #Soleno Therapeutics #DCCR

Kuehn Law Investigates Potential Misconduct by Soleno Therapeutics Executives

Overview
Kuehn Law, a law firm specializing in shareholder litigation, has announced that it is currently examining whether executives at Soleno Therapeutics, Inc. violated their fiduciary duties to the company's shareholders. The investigation stems from allegations made in a federal securities lawsuit.

Background
Soleno Therapeutics, listed on the NASDAQ under the symbol SLNO, is engaged in developing therapies for rare genetic disorders, particularly Prader-Willi Syndrome (PWS). The company's key product, DCCR, is being developed as a treatment for hyperphagia associated with this condition. However, the lawsuit raises significant concerns regarding the integrity of the clinical trials associated with DCCR.

According to the claims, there were serious misconducts related to the handling of the Phase 3 clinical trials. Specifically, it is alleged that details concerning the safety of DCCR were either misrepresented or completely withheld from investors and potential consumers. Safety issues revealed during the trials, such as excessive fluid retention in participants, were reportedly downplayed or concealed by the company and its executives.

As a result of these alleged breaches, the lawsuit states that the risks associated with DCCR were materially greater than what Soleno had disclosed. Investors claim that Soleno's executives failed to provide a clear picture of the commercial viability of DCCR, revealing hidden risks such as:

- Increased patient discontinuation from the treatment.
- Potential adverse regulatory actions.
- Legal ramifications and negative impacts on the company’s reputation.

Call for Action
Kuehn Law is urging current shareholders who purchased SLNO shares prior to March 26, 2025, to come forward, as there may be limited time to assert their rights in this matter. Those interested in discussing their investment and potential legal actions can reach out to attorney Sophia Anne Silayan through her email or phone number provided by the firm. Kuehn Law is committed to not charging its investor clients for legal costs associated with the investigation, ensuring that investors can pursue their rights without financial risk.

Why Your Voice Matters
Kuehn Law emphasizes the importance of shareholder involvement in fostering transparency and accountability within financial markets. By participating in the investigation, shareholders not only contribute to their own financial interests but also uphold the integrity of the investment ecosystem. Shareholders are reminded that “Your investment. Your voice. Your future.” can significantly influence the trajectory of the company and the industry at large.

Conclusion
The investigation by Kuehn Law into Soleno Therapeutics serves as a pivotal reminder of the need for transparency and ethical conduct in the pharmaceutical industry. As the legal proceedings unfold, stakeholders are encouraged to stay informed and engaged. For more details, Kuehn Law invites interested parties to visit their website and stay updated on the status of the investigation.

For further inquiries, shareholders can reach Kuehn Law, PLLC at: